SLC13A5: A Potential Drug Target and Biomarker (G284111)

Target Name: SLC13A5

NCBI ID: G284111

SLC13A5

SLC13A5: A Potential Drug Target and Biomarker

SLC13A5 (also known as EIEE25) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is solute carrier family 13 member 5, and it is a member of the SLC family of transmembrane proteins. SLC13A5 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

SLC13A5 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is primarily localized to the brain, where it is involved in the transport of various substances, including amino acids, neurotransmitters, and water. SLC13A5 is also expressed in other tissues, including the heart and kidneys, where it is involved in the regulation of ion and water transport.

SLC13A5 has been shown to play a role in various physiological processes in the body. For example, it has been shown to be involved in the regulation of neurotransmitter release from the brain, and it has been shown to play a role in the regulation of blood pressure. SLC13A5 has also been shown to be involved in the regulation of ion transport in the brain, which is important for the proper functioning of the brain.

As a potential drug target, SLC13A5 has been the focus of research in recent years. Studies have shown that SLC13A5 is involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that SLC13A5 is involved in the development of neuroblastoma, a type of cancer that affects children, and that it is involved in the progression of Alzheimer's disease, a neurodegenerative disease that affects millions of people worldwide.

In addition to its potential as a drug target, SLC13A5 has also been identified as a potential biomarker for various diseases. For example, studies have shown that SLC13A5 is involved in the regulation of ion transport in the brain, which could make it an attractive biomarker for the diagnosis and treatment of neurodegenerative diseases. In addition, SLC13A5 has been shown to be involved in the regulation of neurotransmitter release from the brain, which could make it an attractive biomarker for the diagnosis and treatment of psychiatric and neurological disorders.

Overall, SLC13A5 is a protein that has important roles in various physiological processes in the body. Its potential as a drug target and biomarker make it an attractive target for research in the field of neuroscience and medicine. Further studies are needed to fully understand the role of SLC13A5 in the development and progression of various diseases, and to develop effective treatments based on its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 13 Member 5

Functions: High-affinity sodium/citrate cotransporter that mediates the entry of citrate into cells, which is a critical participant of biochemical pathways (PubMed:12445824, PubMed:26324167, PubMed:26384929, PubMed:30054523, PubMed:33597751, PubMed:12826022). May function in various metabolic processes in which citrate has a critical role such as energy production (Krebs cycle), fatty acid synthesis, cholesterol synthesis, glycolysis, and gluconeogenesis (PubMed:12826022). Transports citrate into the cell in a Na(+)-dependent manner, recognizing the trivalent form of citrate (physiological pH) rather than the divalent form (PubMed:12445824, PubMed:26324167, PubMed:26384929, PubMed:30054523, PubMed:33597751, PubMed:12826022). Can recognize succinate as a substrate, but its affinity for succinate is several fold lower than for citrate (PubMed:26324167). The stoichiometry is probably 4 Na(+) for each carboxylate, irrespective of whether the translocated substrate is divalent or trivalent, rendering the process electrogenic (PubMed:12445824, PubMed:12826022). Involved in the regulation of citrate levels in the brain (By similarity)

The "SLC13A5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC13A5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets